NVV1.F Novavax, Inc. (XETRA) up 15.65% pre-market 27 Feb 2026: earnings catalyst

NVV1.F stock jumped 15.65% in pre-market trading on 27 Feb 2026 to €9.46, led by an earnings update and heavy volume. The move lifted shares well above the 50-day average of €6.78 and the 200-day average of €6.59 on XETRA in Germany. Traders noted a surge in relative volume at 8.55x, suggesting institutional interest. Meyka AI’s real-time signals flagged the stock as a top gainer ahead of the session.

NVV1.F stock: Pre-market price action and drivers

Novavax, Inc. (NVV1.F) opened the session after an overnight earnings announcement that beat expectations. The stock moved from a previous close of €8.18 to a pre-market high of €10.12, trading at €9.46 at the snapshot.

Volume spiked to 28,684 versus an average of 3,040, producing a relative volume of 8.55. Market participants cited the earnings release dated 26 Feb 2026 and updated trial progress as the primary drivers. See company details and corporate profile on Investing.com for background source.

NVV1.F stock: Fundamentals and valuation snapshot

Novavax reports EPS €1.70 and a PE ratio of 5.72, with a market capitalization near €1.58B. The company shows revenue per share €6.56 and cash per share €4.70, with a current ratio of 2.27.

Key valuation metrics include a price-to-sales ratio of 1.75 and enterprise value to EBITDA of 4.51. These metrics explain why value-oriented traders are active after the earnings surprise. Shares outstanding are 162,498,995, which supports market-cap calculations.

NVV1.F stock: Technicals and trading signals

Technical indicators show bullish momentum after the pre-market jump. The RSI sits at 62.11, MACD histogram is positive, and ADX at 26.73 signals a strong trend.

Bollinger Bands widened with an upper band near €8.20, reflecting higher intraday volatility. The stock is briefly overbought by CCI at 126.17, so short-term pullbacks are possible.

NVV1.F stock: Meyka AI grade and model forecast

Meyka AI rates NVV1.F with a score of 70.80 out of 100 — Grade B+, Suggestion: BUY. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus.

Meyka AI’s forecast model projects a quarterly target of €10.20 and a yearly price of €9.43. Against the current price of €9.46, the quarterly target implies an upside of 7.82%, while the yearly model implies a minor downside of -0.32%. Forecasts are model-based projections and not guarantees.

NVV1.F stock: Catalysts, risks, and sector context

Near-term catalysts include follow-up earnings detail, Phase III trial milestones, and manufacturing updates with partners such as Takeda. The healthcare sector shows muted YTD performance, giving vaccine developers room to outperform.

Risks include clinical trial setbacks, regulatory delays, and biotech-sector volatility. The stock’s 50-day average €6.78 and 200-day average €6.59 provide support levels, while the year high of €10.03 is near-term resistance.

NVV1.F stock: Price targets and trading strategy

Practical price targets for traders: conservative €7.00, base €10.20, and bull €13.50. These targets reflect valuation, trial progress, and the current sentiment shift.

Short-term traders can watch for a pullback to the €7.50–€8.50 zone as a buying opportunity. Longer-term investors should track cash runway and free cash flow, given negative free cash flow per share of €-2.37.

Final Thoughts

NVV1.F stock is a top pre-market gainer on 27 Feb 2026 after an earnings-driven move to €9.46 on XETRA in Germany. The rally shows heavy participation, with 28,684 shares traded and a relative volume of 8.55x, which supports the price breakout. Fundamentals look compelling on EPS €1.70 and PE 5.72, while technicals show strong momentum and short-term overbought readings.

Meyka AI’s models project a quarterly target of €10.20, implying an upside of 7.82% versus the current price. Our proprietary Meyka grade is 70.80/100 (B+, BUY), reflecting positive growth and valuation metrics. Investors should weigh trial and regulatory risks against upside from upcoming catalysts. For real-time updates and deeper metrics consult Meyka AI’s live page for NVV1.F and company filings. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.